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Abstract
Background: Molecular characterization of tumors has been critical for identifying important genes in cancer
biology and for improving tumor classification and diagnosis. Long non-coding RNAs, as a new, relatively
unstudied class of transcripts, provide a rich opportunity to identify both functional drivers and cancer-type-specific
biomarkers. However, despite the potential importance of long non-coding RNAs to the cancer field, no
comprehensive survey of long non-coding RNA expression across various cancers has been reported.
Results: We performed a sequencing-based transcriptional survey of both known long non-coding RNAs and
novel intergenic transcripts across a panel of 64 archival tumor samples comprising 17 diagnostic subtypes of
adenocarcinomas, squamous cell carcinomas and sarcomas. We identified hundreds of transcripts from among the
known 1,065 long non-coding RNAs surveyed that showed variability in transcript levels between the tumor types
and are therefore potential biomarker candidates. We discovered 1,071 novel intergenic transcribed regions and
demonstrate that these show similar patterns of variability between tumor types. We found that many of these
differentially expressed cancer transcripts are also expressed in normal tissues. One such novel transcript specifically
expressed in breast tissue was further evaluated using RNA in situ hybridization on a panel of breast tumors. It was
shown to correlate with low tumor grade and estrogen receptor expression, thereby representing a potentially
important new breast cancer biomarker.
Conclusions: This study provides the first large survey of long non-coding RNA expression within a panel of solid
cancers and also identifies a number of novel transcribed regions differentially expressed across distinct cancer
types that represent candidate biomarkers for future research.
Keywords: 3SEQ, FFPE, human cancer, intergenic transcripts, lncRNAs, novel transcripts, solid tumors, transcriptional
profiling
Background
The differentially expressed genes from hundreds of can-
cer profiling studies over the last several years have yielded
numerous biomarkers that have improved the subtyping,
classification and diagnosis of tumors for both research
and the clinic [1-3]. Because of the extent to which
cancers have been studied by gene microarrays, protein-
coding genes have been well studied in this context.
Recent studies looking beyond protein-coding genes have
shown that microRNAs (miRNAs) can show higher speci-
ficity as biomarkers for some applications than protein-
coding genes. As the landscape of long non-coding RNAs
(lncRNAs) grows, studies have found that lncRNAs also
tend to show more tissue-specific expression than protein-
coding genes [4]. This property of lncRNAs makes them
highly attractive as tissue-specific biomarkers.
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any medium, provided the original work is properly cited.LncRNAs, generally defined as having a size greater than
200 nucleotides, make up a diverse group of non-coding
RNAs that are distinct from miRNAs. Until recently, very
few lncRNAs were annotated within the human genome.
Now, various groups have developed independent catalogs
of human lncRNAs [4-11]. These range from the lncRNA
database containing a few hundred high-confidence,
experimentally validated lncRNAs [12] to the largest of the
lncRNA catalogs, compiled by the GENCODE group, who
combined manual curation, computational analysis and
targeted experimental validation of the GENCODE tran-
script database to predict more than 14,000 lncRNA tran-
scripts from roughly 9,000 gene loci [5,13]. Despite the
thousands of human lncRNAs now predicted, few
lncRNAs have been well characterized to date, so little is
known about the expression patterns of most lncRNAs in
more than a handful of cell types.
Recent analyses suggest that lncRNAs may play key roles
in cancer [14,15]. LncRNAs have been shown to play an
important role in epigenetic gene regulation and cellular
differentiation [16-18], both of which are processes fre-
quently deregulated in cancer. Targeted evaluation of the
lncRNA Hox antisense intergenic RNA (HOTAIR) in a set
of clinical breast cancer specimens showed that HOTAIR
expression was associated with breast cancer metastasis
and acts by disrupting polycomb repressive complex
2-dependent gene silencing [19,20]. Despite the growing
expectation that numerous lncRNAs are important regula-
tors within both normal and cancer biology, no study to
date has performed a survey of lncRNA expression across
a broad range of human cancer types. We hypothesized
that the usage of lncRNAs may be different between nor-
mal tissues and cancer as well as between various cancers.
To address this, we chose to profile lncRNA expression
across a range of primary human tumors and compare
expression patterns against a small sampling of normal tis-
sues. A broad collection of cancers offers a rich resource
for studying the usage of known lncRNAs across a range
of cancer biologies and also provides the opportunity to
identify new lncRNA candidates.
High-throughput sequencing provides a number of
advantages over other profiling methods for this type of
study. Sequencing of polyA+ RNA from the various cancer
samples allows for the profiling of transcriptional patterns
o fp r o t e i n - c o d i n gm R N A sa sw e l la sb o t hk n o w na n d
novel lncRNAs, and any other relatively long polyadeny-
lated transcripts. Traditional RNA sequencing (RNAseq)
has limitations when profiling numerous primary tumor
samples, including the need for high quality RNA, which
is difficult to obtain from formalin-fixed clinical speci-
mens, and the expense associated with deep sequencing of
many samples.
Instead, we chose to profile a diverse set of archived
human cancers using 3’-end sequencing for expression
quantification (3SEQ) [21,22]. This variation on the tradi-
tional RNAseq method enriches for 3’ ends of transcripts
by relying on polyA+ selection of fragmented RNA. Only
the 3’-end-most polyadenylated fragment of each tran-
script is isolated and sequenced, making the technique
especially suitable for archived samples with fragmented
RNA. This ‘sequence tag’ approach (not unlike expressed
sequence tag (EST) libraries) also significantly reduces the
sequencing depth necessary relative to RNAseq, because
RNAseq targets the entire length of each transcript. By
reducing the sequencing to only a 3’ fragment from each
transcript using a polyA+ selection, 3SEQ allowed us to
substantially reduce the depth of sequencing required to
discover and quantify rare RNAs and allowed us to profile
many more samples than would have been possible using
traditional RNAseq. Additionally, because of its strand-
specific libraries, 3SEQ also provided directional infor-
mation for each sequence read, allowing separate
quantification of transcripts on both strands.
Given our interest in exploring lncRNA expression
across a broad range of solid tumors and identifying new
transcripts associated with various cancer types, we chose
to profile a diverse set of solid human tumors representing
adenocarcinomas and squamous cell carcinomas from dif-
ferent organs, as well as a variety of soft-tissue sarcomas.
Although all of these cancer subtypes have been pre-
viously evaluated by gene microarray, this study represents
the first unbiased sequencing-based screen for lncRNAs
and other long novel transcripts across this diverse set of
cancer subtypes.
Results
3SEQ profiling of lncRNAs and novel transcribed regions
To profile known lncRNAs as well as identify and quanti-
tate novel transcripts across a range of solid cancers, we
performed 3SEQ, a 3’-strand-specific sequencing technique
for the quantification of polyA+ RNA [21], to obtain global
gene expression patterns in 64 solid tumors, representing
17 diagnostic classes of both sarcomas and carcinomas.
Over 1.7 billion total short sequence reads were generated,
resulting in more than 409 million reads that mapped
uniquely to the human genome (Table S1 in Additional
file 1). Because the 3SEQ method captures only the 3’
polyadenylated ends of RNA fragments and directionally
sequences the start of the fragments, the resulting sequen-
cing reads cluster into strand-specific peaks when mapped
to the reference human genome. Initial analysis of the
uniquely mapping reads from the 66 libraries (two tumor
samples had duplicate libraries) demonstrated that most
sample libraries possessed reads from at least 24,000 of the
37,576 RefSeq transcripts, and this number did not
increase significantly with deeper sequencing (Figure S1 in
Additional file 2). Raw and processed gene expression data
are available in GEO [GEO:GSE28866].
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Page 2 of 13Because we were particularly interested in the expres-
sion patterns of unannotated transcribed regions and
known lncRNAs, including recently discovered lncRNAs,
we adopted a systematic unbiased analysis approach to
identify clusters of sequencing reads across the genome,
independent of gene annotations. After pooling reads
from all samples, we applied a sliding-window peak-calling
algorithm to identify genomic regions enriched for
sequencing reads (see Methods). Our initial analysis
revealed 54,511 clusters of sequence reads with at least
150 reads across the 66 samples. These peaks, situated
across the genome, had a median length of 196 base pairs
(bp), and represented same-strand clustered sequence
reads. Further filtering and increasing the threshold for
peak inclusion resulted in a dataset containing 36,048
peaks with a median enrichment of 74-fold above back-
ground in at least one sample (see Methods).
We first compared these peaks with a collection of
known protein-coding genes (compiled from RefSeq and
University of California, Santa Cruz (UCSC) known
genes). The genomic coordinates for 21,934 of the peaks
at least partially overlapped exons from annotated pro-
tein-coding genes. When the peaks were compared with
a broader definition of known transcripts (coding and
non-coding from RefSeq, UCSC known genes, GEN-
CODE and UCSC all_mRNA), 23,449 peaks were situated
within the 3’- m o s te x o no fa tl e a s to n ea n n o t a t e dt r a n -
script. When non-3’ exons were included in the analysis,
25,258 peaks were determined to be exonic. Because the
3SEQ sequence reads were from RNA fragments ran-
ging between 200 and 300 bp in length, it was not
unexpected to observe a tight distribution of exonic
peaks approximately 275 bp upstream of the 3’-end of
known genes (Figure 1a).
Although theoretically 3SEQ provides sequence reads
against all polyA+ transcripts present in the samples and
we observed thousands of peaks within protein-coding
genes, we focused our analysis on those peaks that over-
lap known lncRNA genes or are situated in intergenic
regions and may correspond to novel transcripts. Four of
the larger recent lncRNA catalogs were combined and
used as the most current collection of known lncRNA
transcripts [4,10,11,13]. After the 21,934 peaks from cod-
ing genes were excluded, 1,065 peaks overlapped known
lncRNA transcripts. These lncRNAs, most of them iden-
tified in normal tissues or cancer cell lines and previously
unstudied in tumor samples, were expressed in at least
one of the solid tumors in our survey (Tables S2 and S3
in Additional file 1). The vast majority of the remaining
peaks could be ascribed to either exons or introns within
other known transcripts including non-coding tran-
scripts, or regions within 5 kb downsteam of known tran-
scripts that likely represented alternative 3’-ends for
known genes (Table S2 in Additional file 1). Following
removal of peaks within or near known transcripts, we
defined a list of 1,071 intergenic peaks greater than 5 kb
from the nearest known transcript (Tables S2 and S4 in
Additional file 1). These intergenic peaks represented
novel transcribed regions at what could be the 3’-ends of
new independent transcripts. Based on the characteristics
of the peaks from known genes, we infer that the inter-
genic peaks represented sequenced regions located
approximately 275 bp upstream of the 3’-end of novel
polyA+ RNA transcripts.
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Figure 1 Distribution and mean expression of 3SEQ peaks. (a) The distribution plot shows a tight cluster of exonic peaks approximately 275 bp
upstream of the 3’ end of known genes (n = 29,024 peaks in known exons; distances are based on genomic coordinates and not the spliced
transcriptome). (b) Boxplots show the distribution of mean expression levels for each peak by peak category. Raw sequence count data was
normalized by dividing each value by the sample mean, and then taking the square root. Boxes range from the first to the third quartiles. Median
expression is marked with a line. Mean values are 0.799, 0.407 and 0.324 for coding, lncRNA and novel transcripts, respectively. Plots are truncated to
show mean expression values less than 2. Outlier peaks show expression as high as 17.9.
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Page 3 of 13Although knowledge of the novel transcripts’ start, stop
and exon structure is not necessary for analysis of the
3SEQ peak expression data, we performed a preliminary
analysis of the transcript structure of the novel intergenic
peaks by comparing them with predicted transcripts
assembled from a large, publically available RNAseq data-
set from 16 normal human tissues. Scripture was run on
Illumina’s BodyMap RNAseq dataset to predict assembled
transcripts from the RNAseq reads [6,23]. Because this
reference set was assembled using only a handful of nor-
mal samples, it was not surprising that only 402 (37.5%) of
the novel intergenic 3SEQ peaks overlapped with novel
transcripts from the normal dataset. Interestingly, how-
ever, only 72 intergenic peaks overlapped BodyMap multi-
exon transcripts with predicted splice sites. Similar to
results described by van Bakel and colleagues [11], 330
(82.1%) of the overlapping 3SEQ intergenic peaks corre-
sponded to predicted single-exon transcripts in the Body-
Map dataset. Similarly, 558 (52%) of our novel peaks
o v e r l a p p e dw i t hE S T s ,b u to n l y8 8( 8 % )o v e r l a pw i t h
spliced ESTs. Single-exon transcripts have not traditionally
been classified as lncRNAs, but their polyA+ status sepa-
rates them from traditional miRNAs.
To further evaluate our intergenic transcripts with
respect to other annotations, we compared our novel
peaks with a variety of datasets (see Table S4 in Additional
file 1 and Methods). Although 269 intergenic peaks (25%)
overlapped conserved regions, 588 (55%) contained at
least some repetitive sequences. A handful of the inter-
genic peaks corresponded with known genes from GEN-
CODE that are absent from the RefSeq and UCSC gene
annotations: 23 (2.1%) and 13 (1.2%) intergenic peaks
overlapped GENCODE transcripts on the sense and anti-
sense strands, respectively. Another 23 (2.1%) are within
introns of GenBank mRNAs. Likewise, a small number
(25, 2.3%) of the intergenic peaks overlapped ribosomal
RNA pseudogenes, while another 31 (2.9%) overlapped
other pseudogenes. None of the intergenic peaks over-
lapped annotated small nucleolar RNAs or miRNAs, but
66 of the peaks (6.2%) were antisense to other 3SEQ
peaks. Even though the classification and functional status
of most of the 3SEQ intergenic peaks remained unclear,
we were interested in determining if any of these tran-
scripts were associated with specific cancer classes and
could be used as cancer biomarkers.
Expression analysis of lncRNAs and novel transcribed
regions in solid tumors
After identifying lncRNAs and new transcripts expressed
in our panel of tumors, we explored how these RNAs were
expressed across the different types of cancer surveyed.
The sequencing analysis comprised 66 libraries from 64
independent cancer samples representing 17 different
diagnostic classes. Between two and seven samples were
selected to represent each diagnosis, with roughly half of
the samples representing carcinomas (adenocarcinomas,
squamous cell carcinomas and others) and the other half
representing more rare sarcomas. Because the 3SEQ peaks
were identified based on pooled reads from all of the can-
cer samples, the peaks could represent RNAs expressed in
any number of the samples. To assess sample expression
levels, we tallied the total number of 3SEQ reads within
each peak for each sample, and the raw read counts were
normalized between samples to account for the sequen-
cing depth of each library (see Methods).
Globally, the average expression levels of the lncRNA
peaks and the intergenic peaks were reduced relative to
the expression of coding genes (1.96-fold difference for
lncRNAs and 2.46-fold difference for the novel transcripts;
P <2.2 × 10
-16;F i g u r e1 b ) .A v e r a g elncRNA expression
was slightly higher than average expression of the novel
transcripts (P <0.0005; Figure 1b). To examine those tran-
scripts with higher, more variable expression levels across
samples, we selected peaks with a standard deviation
greater than 0.25 (roughly the median expression level of
lncRNA and novel transcripts) across the cancer samples.
This focused our analysis to 368 lncRNA peaks and 297
novel transcribed regions. Strikingly, samples of the same
diagnosis tended to show similar expression levels, with
various combinations of the cancer types showing expres-
sion across the peaks surveyed (Figure 2). Significant
expression differences were shown between the carcino-
mas and sarcomas for 483 of the lncRNAs and 394 of the
novel peaks (false discovery rate (FDR) <0.05). Other
peaks showed specificity for various combinations of the
adenocarcinomas or the squamous cell carcinomas. Many
peaks, however, appeared to show even more specificity,
with expression in only a small fraction of the cancer
types.
To better characterize this specificity and identify
which of the above peaks was differentially expressed in
at least one diagnostic subtype, we performed a two-class
significance analysis using significance analysis of micro-
arrays (SAM) [24] for each of the 17 cancer classes. This
allowed us to identify peaks differentially expressed in
each diagnostic class versus all other classes. These ana-
lyses revealed 267 lncRNAs (72.6%) and 217 novel peaks
(73.1%) were differentially expressed in at least one can-
cer type with an FDR of 0.05 (Figure 2 and Tables S3, S4
and S5 in Additional file 1). Of these peaks showing sig-
nificant differential expression, most peaks (202 lncRNAs
and 189 novel peaks) were significantly expressed in only
one of the 17 diagnostic classes, making these peaks can-
cer-type specific with respect to the other cancers
surveyed.
To confirm the class-specific differential expression
measured by 3SEQ for a subset of 3SEQ peaks, we per-
formed quantitative RT-PCR (qRT-PCR) on 23 peaks in a
Brunner et al. Genome Biology 2012, 13:R75
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Page 4 of 13Figure 2 Variably expressed lncRNAs and novel intergenic transcripts. Heatmaps illustrating the 368 lncRNAs (left) and 297 novel transcripts
(right) with variable expression as defined by standard deviation >0.25 across 66 cancer samples. Transcripts with differential expression in at least one
of the 17 two-class SAM analyses (top) were clustered separately from those transcripts not significantly differentially expressed (bottom). Normalized
read data were median centered, hierarchically clustered and plotted on a low (green) to high (red) heatmap. Samples are grouped by cancer type;
the number in parentheses indicates the number of libraries for each cancer type. Red and pink is used for libraries made from adenocarcinomas of
breast, lung, colon and prostate, as well as normal breast, lung and colon. Orange and yellow show squamous cell carcinomas of the head and neck,
skin, lung and other carcinomas: papillary urothelial carcinoma and nasopharyngeal carcinoma. Green indicates sarcomas with known translocations:
endometrial stromal sarcoma, Ewing’s sarcoma, extraskeletal myxoid chondrosarcoma, synovial sarcoma and myxoid liposarcoma. Blue shows other
sarcomas: gastrointestinal stromal tumor, leiomyosarcoma and dedifferentiated liposarcoma. Normal samples and cancer samples were combined for
hierarchical clustering, but are displayed separately for clarity. Samples are ordered according to Table S1 in Additional file 1. Breast, breast invasive
ductal carcinoma; colon, colon adenocarcinoma; DDLPS, dedifferentiated liposarcoma; EMC, extraskeletal myxoid chondrosarcoma; ESS, endometrial
stromal sarcoma; EWS, Ewing’s sarcoma; GIST, gastrointestinal stromal tumor; HN SCC, head and neck squamous cell carcinoma; LMS, leiomyosarcoma;
Lung, lung adenocarcinoma; Lung SCC, lung squamous cell carcinoma; MLS, myxoid liposarcoma; NPC, nasopharyngeal carcinoma; prostate, prostate
adenocarcinoma; PUC, papillary urothelial carcinoma; Skin SCC, skin squamous cell carcinoma; SS, synovial sarcoma.
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Page 5 of 13subset of the samples profiled by 3SEQ. In this qRT-PCR
analysis, 19 of the 23 peaks had elevated expression in
samples from the diagnostic subtype that previously had
shown elevated expression by3 S E Q( F i g u r eS 2i nA d d i -
tional file 2).
lncRNA and novel transcript expression in normal tissues
Although we observed many lncRNAs and novel tran-
scripts expressed specifically in some cancer types with
respect to others, it was unclear if the transcripts were
specific to cancer or instead were normally expressed
transcripts, likely possessing a function within normal tis-
sue biology, that were also expressed in cancers. To
address how the cancer-expressed lncRNAs and novel
transcribed peaks identified above were expressed in nor-
mal tissues, we performed 3SEQ on 27 normal samples,
including 10 fetal samples from bowel, lung and kidney
at 13 to 15 weeks and 17 adult tissues from normal
breast, colon, kidney, lung and uterus. The number of
3SEQ reads was determined for each of the previously
identified peaks, and the normalized expression data
were analyzed. Just as with expression patterns across the
cancer subtypes, lncRNA and novel peak expression
showed a number of patterns in the normal tissue sam-
ples: some did not appear to be expressed or were
expressed at very low levels, some were expressed across
most normal samples, some were limited to adult sam-
ples, some to fetal samples, and some showed more tis-
sue-specific expression patterns (Figure 2).
Although most of the peaks showed some level of
expression in the normal samples (929 lncRNAs (87%)
and 867 novel peaks (81%) showed greater than 0.4
expression in at least one of the normal samples), generally
the maximally expressing cancer sample showed higher
expression levels than the maximally expressing normal
sample (888 lncRNAs (83%) and 955 novel peaks (89%)).
However, average expression levels for the transcripts
across the cancer and normal samples tended to be com-
parable (R = 0.9635 for lncRNAs and R = 0.9329 for novel
peaks; see Figure S3 in Additional file 2). Because this ana-
lysis did not include normal tissue-of-origin matches for
several of the cancer types, we were interested in further
evaluating expression levels for transcripts in the subset of
cancers with corresponding normal tissues (breast, colon
and lung). Specifically, were the transcripts identified as
highly expressed and specific for cancer subtypes
expressed in their normal tissue counterparts? Indeed, for
those peaks differentially expressed in cancer (13 in breast,
10 in colon, 6 in lung), although the average expression of
the peaks tended to be higher in cancer tissues, most of
the peaks showed evidence of expression in normal tissues
(Figure 3). Interestingly, the breast cancer peaks showed
more comparable expression levels between cancer and
normal tissue, whereas the colon cancer peaks were
expressed at lower levels in normal adult tissue. Two of
the colon cancer peaks showed distinct normal fetal
expression, whereas none of the lung-specific peaks
showed obvious fetal expression. Two of the lung cancer
peaks were highly expressed in normal adult lung tissue.
This case study of a small number of normal counterparts
showed that, although expression patterns between cancer
and normal tissue may vary, the cancer peaks identified in
this study tended to show some level of normal expres-
sion. These findings suggest that many of these transcripts
may have functional roles in normal tissues and their
expression is maintained in the corresponding cancers.
A case study of breast-specific RNAs
We wished to confirm and extend our observations about
lncRNA expression patterns obtained using 3SEQ by
exploring the expression of one of our novel transcripts
using an alternative expression method, RNA in situ
Figure 3 Significant lncRNAs and novel transcripts in breast, lung and colon cancer. LncRNAs and novel transcripts significantly
differentially expressed in (a) breast (n = 13), (b) colon (n = 10) and (c) lung (n = 6) cancers. Normalized, uncentered read data for cancer and
normal samples were hierarchically clustered and plotted on low (black) to high (red) heatmaps.
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Page 6 of 13hybridization. Our 3SEQ profiling efforts relied on RNA
collected from the various cell types comprising heteroge-
neous tissue and tumor samples. We hypothesized that
lncRNA expression is cell-type specific within normal tis-
sues and that this spatial specificity will be recapitulated in
the cancer counterparts. RNA in situ hybridization per-
formed on tissue microarrays allows a quick method for
assessing expression of an RNA of interest across numer-
ous samples in parallel as well as providing additional
information about how the RNA is expressed across cell
types and how it is localized within cells. To this end, we
identified an intriguing set of three breast-specific tran-
scripts (two novel and one lncRNA) showing particularly
high expression levels and located within a 200 kb inter-
genic region on chromosome 10, approximately 50 kb
downstream of the nearest protein-coding gene, the breast
gene ANKRD30A (also known as NY-BR-1;F i g u r e4 a
[25]). An analysis of 3SEQ data from these three peaks,
13741, 13742 and 13743, showed that they were variably
expressed in both normal breast and breast cancer tissue,
but were not expressed in cancers from other tissue types
(Figure S4a in Additional file 2). Because peak 13741 was
the most highly expressed of the three 3SEQ peaks in the
region, we further studied this RNA. Peak 13741 expres-
sion was examined in a panel of 11 breast cancer cell lines
using qRT-PCR (Figure S4b in Additional file 2), and
northern blot analysis was used to determine that peak
13741 corresponded with a long transcript, greater than
5 kb (Figure S4c in Additional file 2).
The genomic coordinates of the 13741 transcript were
unclear because its 3SEQ peak did not overlap any
annotated exons in known genes or pseudogenes. Peak
13742 was annotated as a known lncRNA in our analy-
sis because of its overlap with GENCODE transcript
ENSG00000235687 (Figure 4a). Peak 13742 also corre-
sponded with a spliced transcript predicted by Scripture
using the BodyMap normal breast dataset. To further
study the transcripts within this locus, we performed
transcript prediction using RNAseq data we generated
from six breast cancer cell lines expressing peak 13741
and identified a number of predicted transcripts in this
region (Figure S5 in Additional file 2; [GEO:GSE28866]).
Interestingly, most of the spliced transcripts corresponded
with the 13742 transcript, leaving us with only short sin-
gle-exon transcript predictions (some of them within
introns of the 13742 transcript isoforms) to explain peaks
13741 and 13743. Additionally, the genomic region con-
taining 13741 did not appear to be evolutionarily con-
served, nor did it span any repetitive elements.
Though the full transcript structure for peak 13741
remains to be determined, we used the genomic sequence
spanning peak 13741 to develop an RNA in situ hybridiza-
tion probe (Figure 4b) and evaluated the expression of
peak 13741 on several cancer tissue microarrays. The
RNA in situ hybridization signal representing peak 13741
expression for both invasive breast cancer and normal
breast tissue was confined to the epithelial cells within the
samples (Figure 4c, bottom left). Within the normal breast
tissues examined, expression varied and was present in 5%
to 30% of cells. Strong staining was observed in 127 out of
the 197 invasive breast carcinomas, as defined by greater
than 30% of cells staining, though 81.9% (104 out of 127)
showed staining in the vast majority of the tumor cells
(60% to 95% of tumor cells staining). The probe signal for
all of the positively staining samples appeared localized to
the nucleus (Figure 4c, bottom left), which is distinct from
the cytoplasmic probe signal typically observed when RNA
in situ hybridization is performed on protein-coding
mRNAs. Instead, this nuclear pattern follows the trend for
lncRNAs and other regulatory RNAs, which, with limited
evidence, tend to show nuclear localization [26].
Although the structure and function of the transcript
corresponding with peak 13741 remains to be deter-
mined, we were struck by this transcript’s potential as a
breast cancer biomarker because of the specificity of its
expression across the more than 800 samples surveyed.
Specifically, we found that significant expression was
only present in breast tissue, with peak 13741 showing
no significant expression in other neoplasms or normal
tissues. Because a range of breast cancer subtypes were
present on the tissue microarrays, we were able to deter-
mine that the expression of peak 13741 was positively
associated with low tumor grade (P =6 . 1×1 0
-8), estro-
gen receptor (ER) expression (Figure 4c, top panels, P =
6.4 × 10
-15) and progesterone receptor (PR) expression
(P =6 . 8×1 0
-14) in breast cancers and showed no signifi-
cant association with metastasis or human epidermal
growth factor receptor 2 (HER2) expression (Table 1).
That the expression was correlated with ER+ or PR+
breast cancers and was largely absent from ER- tumors
suggests that the transcript corresponding to peak 13741
may function specifically within normal breast tissue and
low grade ER+ or PR+ breast cancer. Thus, it may be
useful not only as a biomarker to distinguish breast can-
cer subtypes but also as an interesting, possibly regula-
tory RNA in normal breast and breast cancer biology.
Discussion
Recent studies have demonstrated the importance of
lncRNAs in regulating embryogenesis and gene expres-
sion, and there is considerable evidence that this class of
RNAs plays important roles in cancer [14,18,19,27,28].
However, the definition of lncRNAs is still evolving and
even the number of lncRNAs encoded by the human gen-
ome is unclear, making it difficult to survey lncRNA
expression comprehensively. We surveyed lncRNA expres-
sion in cancer by using 3SEQ, a 3’-end targeted RNAseq
method, to determine how lncRNAs are expressed within
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Page 7 of 13Figure 4 A case study of novel, breast-specific peak 13741. (a) Browser shot showing expression for a breast cancer sample in the region
downstream of ANKRD30A on chromosome 10. The first two tracks show the known genes and RNAs in this locus. The third track shows the peaks
identified in this study, including three highly expressed peaks: novel 13741, lncRNA 13742 and novel 13743. The fourth track shows the raw 3SEQ
reads (transcript abundance levels) on the forward strand (blue) and reverse strand (red). The final tracks show the longest transcripts that overlapp e a k
13742, a Scripture-assembled transcript produced using normal breast RNAseq reads from the Illumina BodyMap data set and GENCODE lncRNA
ENSG00000235687. (b) Zoom-in browser shot of peak 13741 on chromosome 10 shows the location of the RNA in situ hybridization probe (top track)
as well as the raw sequence reads for one breast cancer sample (bottom track). This peak illustrates the shape of a typical 3SEQ peak from a high-
expressing transcript. (c) ER staining on an ER+ breast cancer (top left) and an ER-breast cancer (top right). RNA in situ hybridization for peak 13741
performed on the same ER+ breast cancer specimen (bottom left) and same ER- breast cancer (bottom right). Specimens were matched but ER and
13741 stains used different tissue slices. All images are at 400× magnification. 3SEQ, 3’-end sequencing for expression quantification; chr10,
chromosome 10; ER, estrogen receptor; lncRNA, long non-coding RNA.
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novel intergenic transcripts in cancers.
Several groups have compiled catalogs of lncRNAs,
ranging from lists of a few hundred named lncRNAs to
lists of up to 15,000 predicted lncRNAs [12,13]. We com-
pared our peaks with four of the larger lncRNA catalogs.
Three of these catalogs themselves include compilations
of previous catalogs and datasets. Ulitsky and colleagues
assembled a set of 2,458 lncRNAs by computationally fil-
tering transcripts from the RefSeq, Ensembl and UCSC
gene lists [10]. Cabili and colleagues assembled a catalog
using 3,376 lncRNAs from RefSeq, GENCODE and
UCSC and adding 4,819 lncRNAs identified from among
the predicted transcripts assembled from the Human
Body Map RNAseq dataset [4]. Versions 7 to 10 of the
GENCODE lncRNA annotation set, assembled using
manual curation, computational analysis and targeted
experimental validation of GENCODE transcripts com-
piled by the ENCODE project, comprise more than
15,000 transcripts representing more than 9,000 non-
overlapping lncRNA sequences (Derrien et al., sub-
mitted) [5,13,29]. van Bakel and colleagues used a normal
human RNAseq dataset to predict approximately 1,250
novel intergenic lncRNA transcripts [11]. Because the
various catalogs were based on different datasets and
employed different criteria for lncRNA prediction, per-
haps it is not surprising that they did not show high per-
centages of transcript overlap. In addition, these studies
were based on transcripts primarily isolated from normal
tissues and cell lines; no study to date has evaluated these
newest annotated lncRNAs for expression in human can-
c e r s .I nt h i ss t u d y ,w eu s e dt h eu n i o no fa l lo ft h e
lncRNAs from the four catalogs described above as the
reference set for comparisona n ds h o w e dt h a t1 , 0 6 5o f
the 3SEQ peaks expressed in our cancer panel overlap
previously predicted lncRNAs. This allowed us to deter-
mine for the first time the expression patterns for many
of these lncRNAs within primary tumor samples.
We also found 1,071 novel intergenic 3SEQ peaks
expressed in our cancer panel. These RNAs were isolated
using the same polyA+ and size selection used to capture
the lncRNAs and the >21,000 protein-coding mRNAs. We
therefore inferred that the novel intergenic peaks were
derived from long (>200 bp) polyA+ transcripts; however,
overlap analysis with Scripture-predicted transcripts sug-
gested that some of these novel transcripts were single-
exon transcripts. Although both the levels and patterns of
gene expression across the novel intergenic peaks
appeared similar to the lncRNA peaks, suggesting that
these novel peaks may be new lncRNAs, these peaks also
resembled the short intergenic transcripts described by
others [11]. Further characterization of these novel tran-
scripts will be required to determine their structure and
functional importance within cancer.
Profiling of the non-coding transcriptome in primary
human cancers has been limited, despite the evidence that
lncRNAs are important players in gene regulation. We
therefore performed unbiased expression profiling on a
diverse panel of solid cancers, representing 17 diagnostic
subclasses of adenocarcinomas, squamous cell carcinomas
and sarcomas. We identified 267 lncRNAs and 217 novel
transcribed regions that were differentially expressed in at
least one of the cancer types. Differential expression has
been used as an important filtering parameter for identify-
ing genes that are not only correlated with but potentially
functionally important in various cancer types. Despite the
limited number of samples representing each diagnosis,
we were struck by the extent of specificity of some of
these transcripts. Though many of the transcripts
appeared to show some expression in the normal samples
examined, these differentially expressed transcripts are
intriguing candidates for both future study and more
immediately for biomarker analyses.
Because previous cancer studies performed on lncRNAs
have been small-scale studies using a less comprehensive
collection of cancer samples, it has been difficult to make
any generalizations about whether the expression of
lncRNAs differs between cancer and normal tissue. We
took the opportunity to address this question by analyzing
3SEQ expression for the cancer-expressed lncRNA peaks
and novel transcripts within 27 normal tissues. Although
our analysis was limited to only a handful of types of nor-
mal tissues, we observed that the lncRNAs profiled in this
study and expressed in cancer tended to have at least
some expression in the normal samples. Therefore, the
cancer-expressed lncRNAs may not to be specific to can-
cer, but most likely have some function in normal tissues.
It also does not appear that lncRNAs, as a class, have sig-
nificantly different expression levels between cancer and
normal tissue. More striking, however, was that many can-
cer-expressed lncRNAs and novel transcripts showed tis-
sue-specific expression patterns and, for some cancers, the
normal tissue-of-origin expression patterns appeared to be
maintained in the associated cancers. Further research is
needed to determine the function and importance of the
Table 1 Novel, breast-specific peak 13741 is associated
with estrogen-receptor-positive and progesterone-
receptor-positive cells and Grade 1 breast cancer
ER+ ER- PR+ PR- Grade 1 Grade 3
(n = 146) (n = 33) (n = 129) (n = 50) (n = 42) (n = 41)
13741+ 122
(83.6%)
5
(15.2%)
112
(86.8%)
15
(30.0%)
37
(88.1%)
12
(29.3%)
13741- 24
(16.4%)
28
(84.8%)
17
(13.2%)
35
(70.0%)
5
(11.9%)
29
(70.7%)
RNA in situ hybridization results for analyses correlating the expression of
peak 13741. Numbers of samples are reported. Each test was significant by
the Kruskal-Wallis rank sum test. +, staining in >30% of cells; -, staining in
<10% of cells; ER, estrogen receptor; PR, progesterone receptor.
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biology.
RNA in situ hybridization allowed us to further charac-
terize the expression of a novel breast-specific transcript,
peak 13741, across hundreds of cancer and normal patient
samples. We demonstrated that the transcript was not
only tissue-specific (expressed only in breast and breast
cancers), it was cell-type specific (expressed in epithelial
breast cells and not the surrounding stromal cells) and
had specific cellular localization patterns (nuclear, as
opposed to cytoplasmic). All of these observations suggest
that this transcript has regulated transcription and may
have a functional role within breast tissue biology. The
correlated expression of this transcript with ER in breast
cancer and the apparent loss of expression of this tran-
script in ER- breast cancer suggest that this transcript may
be functioning within the ER pathway. Further research is
necessary to determine the function of the peak 13741
transcript, because of its strong correlation with ER+ and
PR+ breast cancers, but this peak has potential as a useful
breast cancer biomarker.
Conclusions
This study represents the first large survey of lncRNA
expression across a diverse panel of primary human cancer
samples and provides the research community with a valu-
able resource for cancer-expressed lncRNAs as well as a
collection of novel transcripts expressed within cancers.
We illustrate that 3SEQ can be used for transcriptional
profiling to identify both known lncRNAs and novel tran-
scripts within archived primary tissue samples, and our
RNA in situ hybridization analysis of one such novel RNA,
peak 13741, identified it as an intriguing breast-specific
RNA that may be important for the differences between
ER+ and ER- breast cancers.
Methods
Tissue samples
Tumor and normal samples were collected using writ-
ten informed consent compliant with the Health Insur-
ance Portability and Accountability Act and approved
by the Stanford University Medical Center institutional
review board. Some of the tissues already existed in tis-
sue banks and fell under exemption 4. For this study,
we selected 64 formalin-fixed paraffin-embedded (FFPE)
cancer samples, along with 27 normal samples, follow-
ing examination of hematoxylin and eosin stains by
pathologists RBW and MvdR. Multiple 2 mm-diameter
cores were taken from each FFPE block, re-embedded
in paraffin at a perpendicular orientation, and then
sliced into 4-μm-sections for further hematoxylin and
eosin examination or 20-μm-sections for nucleic acid
extraction. Approximately one hundred 20-μm-slices
were placed into one to two 1.5 mL tubes for nucleic
acid isolation. (See Table S1 in Additional file 1 for
sample numbers and diagnoses.)
RNA isolation and 3SEQ library preparation
RNA was purified from FFPE slices following deparaffina-
tion with a xylene incubation, ethanol wash and protease
digestion, using the RecoverAll Total Nucleic Acid Isola-
tion Kit (Ambion/Life Technologies, Austin, TX, USA),
as described previously [21]. Isolation of the 3’-ends of
mRNA was achieved with an oligodT selection per-
formed on at least 5 μg total RNA using the Oligotex
mRNA mini Kit (QIAgen, Valencia, CA, USA). RNA that
was not sufficiently fragmented was heat-sheared to a
size of approximately 100 to 200 bp. The polyA+ RNA
was then subjected to first and second strand cDNA
synthesis and Illumina library synthesis, as described pre-
viously [21]. (Duplicate 3SEQ libraries were created for
two cancer samples: ESSSTT5520 and LMS STT516.)
Sequencing and mapping
3SEQ libraries were sequenced with Illumina Genome
Analyzer IIx machines to obtain a minimum of 1.5 mil-
lion uniquely mapping 25-base single-end sequence
reads. Reads were mapped to hg18 with a two-mismatch
allowance using ELAND (Illumina Inc., San Diego, CA,
USA). Sequence reads were further filtered to remove
mapping artifacts caused by ambiguous mapping by
requiring a posterior probability of at least 0.8 for the
best alignment, where posterior probability was calcu-
lated as the ratio of the likelihood of the best alignment
to the sum of the likelihoods of all alignments. Likelihood
was taken from a binomial model of sequencing errors
with constant substitution rate 0.01. FASTQ files and fil-
tered bed files of hg18-mapped reads are available in
[GEO:GSE28866].
Peak analysis
Detection of genomic regions enriched for sequencing
reads (peak-calling) was performed once, by combining
filtered sequence reads from all 66 cancer libraries and
using a custom Perl script to call genomic regions with
greater than 150 reads across all samples. This provided
a single set of genomic peak coordinates, which allowed
for direct comparison of all samples. Because of our
interest in identifying peaks expressed in only a fraction
of samples, we initially selected a more permissive overall
threshold, corresponding with roughly a two-fold enrich-
m e n ta b o v et h a te x p e c t e db yc h a n c ew h e na p p l y i n ga
uniform distribution model for reads from all samples
across the mappable genome. During this process, clus-
ters of sequence reads, each within 20 bp of their nearest
same-strand neighbor, were identified and the coordi-
nates for these genomic regions were defined using the
start coordinates for the left-most and right-most
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then filtered to exclude any region that contained fewer
than 25 different starting positions for the reads within
the region, and in this way required each peak to possess
a minimum of 25 unique reads. The initial list of 54,511
peaks was further filtered to remove peaks antisense to
peaks in known genes (determined to be artifacts of
library preparation). Applying a more stringent threshold
requiring peaks to possess at least 200 total reads
resulted in a filtered list of 36,048 peaks. Assuming a uni-
form distribution of reads to calculate expected back-
ground levels, we determined that peaks on this list were
at least 2.5-fold enriched above background when all
samples were considered or at least four-fold enriched
above background in at least one sample. Most peaks
were enriched well above this level (median = 74-fold
enrichment; see Tables S3 and S4 in Additional file 1 for
fold-enrichment values). Peaks were annotated as coding
genes if they overlapped any exons within annotated cod-
ing genes from the RefSeq and UCSC known gene data-
sets. Peaks were then overlapped with genomic
coordinates for the lncRNA transcripts from the follow-
ing datasets: Ulitsky et al. (n = 2,642) [10]; Cabili et al.
(n = 14,309) [4]; GENCODE lncRNA annotation sets ver-
sion 7 (n = 15,207), version 9 (n = 18,878) and version 10
(n = 17,547) [5,13,29]; and van Bakel et al. (n = 1,252)
[11]. The remaining peaks were determined to be novel
intergenic peaks if they did not overlap promoter regions
(within 5 kb), exons, introns or downstream regions
(within 5 kb) of any known genes from the RefSeq,
UCSC Known Genes, GENCODE or all_mRNA (UCSC
genome browser) datasets. Overlap analysis was used to
further characterize the novel transcripts using several
datasets downloaded from the UCSC genome browser,
including all_ests, spliced_ests, phastConsElements17way
(17way conservation), phastConsElements28wayPlac-
Mammal (28way conservation), rmsk (RepeaterMasker),
wgRna (small nucleolar RNAs, miRNAs), GENCODE
genes and rnaGene. Pseudogenes were obtained from
Pseudogene.org [30,31]. Files with raw counts of the
sequence reads within each 3SEQ peak, as well as the
normalized peak data, are available in [GEO:GSE28866].
Gene expression analysis
The number of sequence reads located within each peak
was determined for each sample. This raw read count data
were then normalized for each 3SEQ peak using the
sequencing depth of each sample by scaling by the mean
value of each sample. Data were further compressed to
reduce outliers by taking the square root of each value.
Correlations between technical replicate libraries were
determined to be r
2 = 0.91 and 0.95. Differential expres-
sion was determined using a series of two-class SAM ana-
lyses [24]. For each of the 17 cancer types, a two-class
comparison of the specific cancer type versus all other
cancers was performed to determine differentially
expressed genes at an FDR <0.05. Using a two-class FDR
of 0.05 to define differential expression, we calculated an
overall FDR for identifying a peak as differentially
expressed in at least one of the 17 two-class SAM analyses
(overall FDR = 0.04). LncRNA and novel transcript expres-
sion were hierarchically clustered using the average linkage
method in Cluster3 and visualized using Java TreeView
(Figures 2 and 3).
Quantitative RT-PCR
cDNA was made from the same total RNA used for the
3SEQ libraries in this study using the DyNAmo™ cDNA
Synthesis Kit (Finnzymes/ThermoScientific, Lafayette,
CO, USA). Primers were designed against 23 peak
sequences using Primer3 and qRT-PCR was performed
using the SYBR green method on a StepOnePlus instru-
ment (Applied Biosystems/Life Technologies, Foster City,
CA, USA) according to the manufacturer’si n s t r u c t i o n s .
Data were normalized using a series of five housekeeping
genes (ARL8B, CTBP1, CUL1, PAPOLA and ACTB). For
qRT-PCR on breast cancer cell lines, cDNA was ampli-
fied using primers against 13741 as described above and
normalized using ACTB. See Table S6 in Additional file 1
for primer sequences.
Breast cancer cell lines
HCC1419, HCC1500, UACC-812, ZR-75-30, CAMA-1,
MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-436 and
MDA-MB-468 were obtained from American Type Cul-
ture Collection (Manassas, VA, USA), whereas SUM 44PE
and SUM 52PE were a kind gift from Dr Stephen Ethier.
Cells were grown to 70% to 80% confluence, and total
RNA was isolated using the QIAgen RNeasy Mini Kit
(QIAgen).
RNAseq on breast cancer cell lines
Six breast cancer cell lines were used for transcriptome
sequencing. RNAseq libraries were prepared using the
Illumina mRNA-Seq Sample Prep Kit (Illumina, Inc.) as
described previously [32]. Illumina Genome Analyzer IIx
machines were then used to sequence paired-end 36mer
reads, which were subsequently mapped to hg18 using
TopHat and assembled into predicted transcripts using
Scripture [6]. RNAseq data for the breast cancer cell lines
are available in [GEO:GSE28866].
Northern blot
Five micrograms of total RNA from UACC-812 and
MDA-MB-436 were used as directed in the NorthernMax
Kit (Life Technologies, Grand Island, NY, USA). To gener-
ate radioactive RNA probes, primers with SP6 polymerase
binding sites were designed to amplify genomic DNA at
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manner (see Table S7 in Additional file 1 for primer
sequences). In vitro transcription reactions were carried
out using [ -
32P]-UTP as directed in the SP6 MAXIscript
Kit (Life Technologies). Following 13741 probe hybridiza-
tion, the blot was stripped and re-probed for b-actin. The
northern blot was exposed to maximum sensitivity film at
-80°C with an intensifier screen for 24 hours for the 13741
hybridization and maximum resolution film for 2 hours
for the b-actin hybridization.
RNA in situ hybridization
The RNA in situ hybridization probe for peak 13741 was
designed against chr10:37,634,173-37,634,625 (hg18)
using primer 5’-TTGGAAAGCCAAATTGTTGA-3’ and
the T7 promoter-tagged primer 5’-CTAATACGACTCA
CTATAGGGTGTTTGTGTTCCCCCATTTT-3’.T h e
digoxigenin-labeled antisense RNA probe was generated
by PCR amplification and in vitro transcription using the
DIG RNA labeling kit and T7 polymerase according to
the manufacturer’s protocol (Roche Diagnostics, Indiana-
polis, IN, USA). RNA in situ hybridization using the
13741 probe on a tissue microarray containing 197 breast
cancers with clinical outcome data was performed as
described previously [33]. Controls included known
negative tissue types and other probes that were non-
reactive. Additional tissue microarrays also tested for
13741 staining included ductal carcinoma in situ (n =
253), normal breast (n = 30) and a collection of other
normal specimens (n = 17) including skin, adrenal gland,
kidney, placenta, gallbladder, ovary, prostate, pancreas,
salivary gland and thymus. Neoplasms tested for 13741
staining (n = 402) were from esophagus, liver, stomach,
pancreas, kidney, colon, ovary, bladder, testes, skin, pros-
tate, lung and uterus. Positive signal was defined as stain-
ing in at least 30% of tumor cells; staining in less than
10% of tumor cells within a case was considered negative.
Several metrics were tested for association with expres-
sion of peak 13741, including ER expression, PR expres-
sion, tumor grade, human epidermal growth factor
receptor 2 expression and the presence of metastasis using
the Kruskal-Wallis rank sum test. Only Grade 1 and 3
tumors were used in the association with peak 13741.
Additional material
Additional file 1: Supplemental tables 1-7. Table S1 shows the
sequencing statistics for the 3SEQ libraries. Table S2 shows the numbers
of 3SEQ peaks overlapping lncRNAs and other annotation classes. Table
S3 lists the 1,065 known lncRNAs. Table S4 lists the 1,071 novel
intergenic peaks. Table S5 shows the number of peaks differentially
expressed in each diagnostic class. Table S6 includes primer sequences
used in qRT-PCR experiments. Table S7 includes primer sequences used
for the northern blot probes.
Additional file 2: Supplemental figures 1-5. Figure S1 plots
sequencing depth versus RefSeq transcripts detected by 3SEQ. Figure S2
shows differential expression for the 23 peaks examined by qRT-PCR.
Figure S3 plots the mean expression in cancer versus the mean
expression in normal samples. Figure S4 shows expression of peak 13741
by 3SEQ, qRT-PCR and northern blot. Figure S5 is a browser shot
showing the predicted breast transcripts near peak 13741.
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